Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05257408 · ClinicalTrials.gov registry record · Phase 3
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
A Phase 3 study of Peritoneal Neoplasms and Fallopian Tube Neoplasms, sponsored by Corcept Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 381
- Enrollment target
- 20
- Study locations
NCT05257408: Active Phase 3 study of Peritoneal Neoplasms and Fallopian Tube Neoplasms, sponsored by Corcept Therapeutics.
NCT05257408 is a Phase 3 study of Peritoneal Neoplasms and Fallopian Tube Neoplasms that is active but no longer recruiting, run by Corcept Therapeutics. The registered enrollment target is 381 participants, roughly in line with the 411-participant average among 14 other Peritoneal Neoplasms trials with a reported enrollment target. The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05257408, a Phase 3 study of Peritoneal Neoplasms and Fallopian Tube Neoplasms, is active but no longer recruiting, sponsored by Corcept Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 381 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of Relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.
Primary Outcome
Time from randomization until the time of first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause, whichever occurs first
Conditions Studied
Interventions
- DRUG Relacorilant 150 mg once daily (QD)
- DRUG Nab-paclitaxel 80 mg/m^2
- DRUG Nab-paclitaxel 100 mg/m^2
Study Locations (20)
California
- Site 350 - Irvine
- Site 364 - La Jolla
- Site 150 - Palo Alto
- Site 278 - San Francisco
- Site 014 - San Francisco
- Site 316 - Solvang
Georgia
- Site 009 - Atlanta
- Site 272 - Atlanta
- Site 372 - Gainesville
- Site 291 - Savannah
Illinois
- Site 315 - Evanston
- Site 314 - Hinsdale
- Site 346 - Urbana
Arizona
- Site 318 - Phoenix
- Site 277 - Tucson
Florida
- Site 335 - Miami Beach
- Site 042 - Weston
Colorado
- Site 032 - Aurora
Indiana
- Site 339 - Indianapolis
Kansas
- Site 200 - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 381 participants |
| Start Date | 2022-06-29 |
| Est. Completion | 2026-03 |
| Phase | Phase 3 |
What the registry record for NCT05257408 still lists
NCT05257408 is an interventional study that assigns participants to a tested intervention. The registered 381 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 411-participant average among 14 other Peritoneal Neoplasms trials with a reported enrollment target.
The record links to 3 conditions, with Peritoneal Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Relacorilant 150 mg once daily (QD) is the first listed.
NCT05257408 names 20 study sites across 8 states, led by California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT05257408 about?
NCT05257408 is a clinical study titled "Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer". The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of Relacorilant in combination with nab-pacli...
What is the current status of trial NCT05257408?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 381 participants. The study started on 2022-06-29. Estimated completion is 2026-03.
What conditions does trial NCT05257408 study?
This clinical trial studies the following conditions: Peritoneal Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasm.
What interventions are being tested in trial NCT05257408?
The interventions under investigation include: Relacorilant 150 mg once daily (QD) (DRUG), Nab-paclitaxel 80 mg/m^2 (DRUG), Nab-paclitaxel 100 mg/m^2 (DRUG).
Who is sponsoring clinical trial NCT05257408?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05257408 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peritoneal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05257408's enrollment target sits among peer trials
381 6th of 14 higher than 9 of 14 other Peritoneal Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peritoneal Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
RECRUITING · Phase 3
-
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
ACTIVE NOT RECRUITING · Phase 3
-
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
COMPLETED · Phase 3
-
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
COMPLETED · Phase 3
-
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05677490 · 382 participants · Phase 3
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- NCT06196008 · 382 participants · NA
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
- NCT07100990 · 382 participants · Phase 3
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI